Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension

[1]  O. Sitbon,et al.  Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension , 2021, Advances in Therapy.

[2]  Y. Rao,et al.  Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension , 2020, Lung.

[3]  V. Sintchenko,et al.  Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? , 2019, European Respiratory Journal.

[4]  V. Cottin,et al.  INITIAL TREATMENT COMBINATION WITH MACITENTAN AND TADALAFIL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE OPTIMA STUDY , 2019, Chest.

[5]  V. McLaughlin,et al.  Macitentan in pulmonary hypertension (PH): Data from OPUS and OrPHeUS real-world data sets , 2019, Pulmonary hypertension.

[6]  P. De Groote,et al.  Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. , 2019, The Lancet. Respiratory medicine.

[7]  M. Gatzoulis,et al.  Evaluation of Macitentan in Patients With Eisenmenger Syndrome , 2018, Circulation.

[8]  Z. Jing,et al.  Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. , 2017, The Lancet. Respiratory medicine.

[9]  S. Rosenkranz,et al.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.

[10]  M. Humbert,et al.  Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. , 2016, The Lancet. Respiratory medicine.

[11]  R. Benza,et al.  Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.

[12]  T. Fleming,et al.  Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  R. Barst,et al.  From Short-Term Benefits to Long-Term Outcomes: The Evolution of Clinical Trials in Pulmonary Arterial Hypertension , 2013, Pulmonary circulation.

[14]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[15]  R. Benza,et al.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.

[16]  H. Farber.  Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? , 2012, Circulation.

[17]  W. Seeger,et al.  Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  T. Fleming,et al.  Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. , 2011, Chest.

[19]  T G Clark,et al.  Survival Analysis Part I: Basic concepts and first analyses , 2003, British Journal of Cancer.

[20]  Douglas G Altman,et al.  Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.